pubmed.ncbi.nlm.nih.gov

Artificial and bioartificial support systems for liver failure - PubMed

Review

Artificial and bioartificial support systems for liver failure

J P Liu et al. Cochrane Database Syst Rev. 2004.

Abstract

Background: Artificial and bioartificial liver support systems may 'bridge' patients with acute or acute-on-chronic liver failure to liver transplantation or recovery.

Objectives: To evaluate beneficial and harmful effects of artificial and bioartificial support systems for acute and acute-on-chronic liver failure.

Search strategy: Trials were identified through The Cochrane Hepato-Biliary Group Controlled Trials Register (September 2002), The Cochrane Central Register of Controlled Trials on The Cochrane Library (Issue 3, 2002), MEDLINE (1966 - September 2002), EMBASE (1985 - September 2002), and The Chinese Biomedical Database (September 2002), manual searches of bibliographies and journals, authors of trials, and pharmaceutical companies.

Selection criteria: Randomised clinical trials on artificial or bioartificial support systems for acute or acute on-chronic liver failure were included irrespective of blinding, publication status, or language. Non-randomised studies were included in explorative analyses.

Data collection and analysis: Data were extracted independently by three reviewers. Results were presented as relative risks (RR) with 95% confidence intervals (CI). Sources of heterogeneity were explored through sensitivity analyses and meta-regression. The primary outcome was mortality.

Main results: Twelve trials on artificial or bioartificial support systems versus standard medical therapy (483 patients) and two trials comparing different artificial support systems (105 patients) were included. Most trials had unclear methodological quality. Compared to standard medical therapy, support systems had no significant effect on mortality (RR 0.86; 95% CI 0.65-1.12) or bridging to liver transplantation (RR 0.87; 95% CI 0.73-1.05), but a significant beneficial effect on hepatic encephalopathy (RR 0.67; 95% CI 0.52-0.86). Meta-regression indicated that the effect of support systems depended on the type of liver failure (P = 0.03). In subgroup analyses, artificial support systems appeared to reduce mortality by 33% in acute-on-chronic liver failure (RR 0.67; 95% CI 0.51-0.90), but not in acute liver failure (RR 0.95; 95% CI 0.71-1.29). Two trials comparing artificial support systems showed significant mortality reductions with intermittent versus continuous haemofiltration (RR 0.58; 95% CI 0.36-0.94) and no significant difference between five versus ten hours of charcoal haemoperfusion (RR 1.03; 95% CI 0.65-1.62). The incidence of adverse events was inconsistently reported.

Reviewer's conclusions: This Review indicates that artificial support systems may reduce mortality in acute-on-chronic liver failure. Artificial and bioartificial support systems did not appear to affect mortality in acute liver failure. However, considering the strength of the evidence additional randomised clinical trials are needed before any support system can be recommended for routine use.

PubMed Disclaimer

Conflict of interest statement

None known. We certify that we have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (e.g., employment, consultancy, stock ownership, honoraria, expert testimony).

Figures

1.1
1.1. Analysis

Comparison 1 Support systems versus standard medical therapy, Outcome 1 Mortality.

1.2
1.2. Analysis

Comparison 1 Support systems versus standard medical therapy, Outcome 2 Bridging to transplantation.

1.3
1.3. Analysis

Comparison 1 Support systems versus standard medical therapy, Outcome 3 Hepatic encephalopathy.

1.4
1.4. Analysis

Comparison 1 Support systems versus standard medical therapy, Outcome 4 Adverse events.

2.1
2.1. Analysis

Comparison 2 Different support systems, Outcome 1 Mortality.

3.1
3.1. Analysis

Comparison 3 Sensitivity analyses, Outcome 1 Mortality in acute and acute‐on‐chronic liver failure.

3.2
3.2. Analysis

Comparison 3 Sensitivity analyses, Outcome 2 Mortality in worst‐case scenario analysis.

4.1
4.1. Analysis

Comparison 4 Non‐randomised studies, Outcome 1 Mortality.

Update of

  • doi: 10.1002/14651858.CD003628

Similar articles

Cited by

References

References to studies included in this review

Bion 1993 {published data only}
    1. Bion JF, Bowden MI, Chow B, Honisberger L, Weatherley BC. Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. Intensive Care Medicine 1993;19:S94‐S98. - PubMed
Davenport 1989 {published data only}
    1. Davenport A, Will EJ, Davison AM, Swindells S, Cohen AT, Miloszewski KJA, et al. Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy. Nephron 1989;53:142‐6. - PubMed
Davenport 1993 {published data only}
    1. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney International 1993;43(Suppl 41):S245‐S251. - PubMed
Denis 1978 {published data only}
    1. Denis J, Opolon P, Nusinovici V, Granger A, Darnis F. Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. Gut 1978;19:787‐93. - PMC - PubMed
Ellis 1996 {published data only}
    1. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, et al. Pilot‐controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24(6):1446‐51. - PubMed
    1. Ellis AJ, Wendon J, Hughes R, Langley P, Sussman NL, Kelly JH, et al. A controlled trial of the Hepatix extracorporeal liver assist device (ELAD) in acute liver failure [abstract]. Hepatology 1994;20(Suppl):140A. - PubMed
Ellis 1999 {published data only}
    1. Ellis AJ, Hughes RD, Nicholl D, Langley PG, Wendon JA, O'Grady JG, et al. Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic‐DT. The International Journal of Artificial Organs 1999;22(1):27‐34. - PubMed
Gazzard 1974 {published data only}
    1. Gazzard BG, Portmann B, Weston MJ, Langley PG, Murray‐Lyon IM, Dunlop EH, et al. Charcoal hemoperfusion in the treatment of fulminant hepatic failure. The Lancet 1974;1(7870):1301‐7. - PubMed
Gimson 1982 {published data only}
    1. Gimson AES, Braude S, Mellon PJ, Canalese J, Williams R. Earlier charcoal hemoperfusion in fulminant hepatic failure. The Lancet 1982;2(8300):681‐3. [MEDLINE: ] - PubMed
He 2000 {published data only}
    1. He JQ, Chen CY, Deng JT, Qi HX, Zhang XQ, Chen JQ. Clinical study on the treatment of fatal hepatitis with artificial liver support system. Chinese Critical Care Medicine 2000;12(2):105‐8.
Heemann 2001 {unpublished data only}
    1. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Broelsch C, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949‐58. - PubMed
Hughes 1994 {published data only}
    1. Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R. Evaluation of the BioLogic‐DT sorbent‐suspension dialyser in patients with fulminant hepatic failure. The International Journal of Artificial Organs 1994;17(12):657‐62. - PubMed
Jiang 2000 {published data only}
    1. Jiang YS, Chen YM, Yao JL, Li XJ, Zeng CH, Deng Y, et al. Evaluation of the therapeutic effect of artificial liver support system on severe viral hepatitis. Chinese Journal of Internal Medicine 2000;39(2):115‐7.
Kramer 1998 {published data only}
    1. Kramer L, Gendo A, Madl C, Ferrara I, Funk G, Schenk P, et al. Biocompatibility of a cuprophane charcoal‐based detoxification device in cirrhotic patients with hepatic encephalopathy. American Journal of Kidney Diseases 2000;36(6):1193‐200. - PubMed
    1. Kramer L, Gendo A, Madl C, Mullen K, Kaminski‐Russ K, Zauner C, et al. A controlled study of the BioLogic‐DT System in chronic hepatic encephalopathy (abstract). Hepatology 1998;28:401A.
    1. Kramer L, Gendo A, Madl C, Mullen KD, Kaminski‐Russ K, Sunder‐Plassmann G, et al. A controlled study of sorbent suspension dialysis in chronic liver disease and hepatic encephalopathy. The International Journal of Artificial Organs 2001;24(7):434‐42. - PubMed
Li 1997 {published data only}
    1. Li LJ, Huang JR, Chen JH, Zhu Z, Chen YM, Gan MJ. The study of treatment of hepatitis gravis by artificial liver support system. Chinese Journal of Hepatology 1997;5(4):202‐3.
Margulis 1989 {published data only}
    1. Margulis MS, Erukhlmov EA, Andreiman LA, Viksna LM. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. Resuscitation 1989;18:85‐94. - PubMed
Mazariegos 1997 {published data only}
    1. Ash SR, Knab WR, Blake DE, Carr DJ, Harker KD, Levy H. The BioLogic‐DTPF System in treatment of fulminant hepatic failure: preliminary results of a clinical trial [Abstract]. Hepatology 1998;28(4):496A. - PubMed
    1. Ash SR, Kuczek T, Blake DE, Gingrich CH. Liver dialysis in treatment of hepatic failure and hepatorenal failure: randomized clinical trials and clinical experience. ASAIO Journal 2000;46:223.
    1. Ash SR, Leamon KB, Gingrich CH. Hemodiabsorption (The BioLogic‐DT System) in treatment of hepatic failure with encephalopathy: summary of randomized, prospectively controlled clinical trials [Abstract]. Hepatology 1998;28(4):496A.
    1. Ash SR, Steczko J, Knab WR, Blake DE, Carr DJ, Harker KD, et al. Push‐pull sorbent‐based pheresis and hemodiabsorption in the treatment of hepatic failure: preliminary results of a clinical trial with the BioLogic‐DTPF System. Therapeuitic Apheresis 2000;4(3):218‐28. [MEDLINE: ] - PubMed
    1. Ash SR, Wilkinson A, Hughes R, Williams R. BioLogic‐DT System in treatment of acute hepatic coma: results of randomized, controlled trials [Abstract]. ASAIO Journal 1996;42(1):11.
Mitzner 2000 {published data only}
    1. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transplantation 2000;6(3):277‐86. [MEDLINE: ] - PubMed
O'Grady 1988 {published data only}
    1. O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94(5 Pt 1):1186‐92. [MEDLINE: ] - PubMed
Redeker 1973 {published data only}
    1. Redeker AG, Yamahiro HS. Controlled trial of exchange‐transfusion therapy in fulminant hepatitis. The Lancet 1973;1(7793):3‐6. [MEDLINE: ] - PubMed
Silk 1978 {published data only}
    1. Silk DBA, Williams R. Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis. The International Journal of Artificial Organs 1978;1(1):29‐33. - PubMed
Stevens 2001 {published data only}
    1. Stevens C, Busuttil R, Han S, Baquerizo A, Fair J, Shrestha R, et al. An interim analysis of a phase II/III prospective randomized multicenter controlled trial of the Hepat Assist Bioartificial Liver Support System for the treatment of fulminant hepatic failure [abstract]. Hepatology 2001;4:299A.
Wilkinson 1998 {published data only}
    1. Wilkinson AH, Ash SR, Nissenson AR. Hemodiabsorption in treatment of hepatic failure. Journal of Transplant Coordination 1998;8(1):43‐50. - PubMed

References to studies excluded from this review

Ash 1992 {published data only}
    1. Ash SR, Blake DE, Carr DJ, Carter C, Howard T, Makowka L. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic‐DT). The International Journal of Artificial Organs 1992;15(3):151‐61. - PubMed
Chen 1996 {published data only}
    1. Chen SC, Hewitt WR, Watanabe FD, Eguchi S, Kahaku E, Middleton Y, et al. Clinical experience with a porcine hepatocyte‐based liver support system. The International Journal of Artificial Organs 1996;19(11):664‐9. - PubMed
Chen 1997 {published data only}
    1. Chen SC, Mullon C, Kahaku E, Watanabe F, Hewitt W, Eguchi S, et al. Treatment of severe liver failure with a bioartificial liver. Annals of the New York Academy of Sciences 1997;831:350‐60. [MEDLINE: ] - PubMed
Chen 1999 {published data only}
    1. Chen JL, Che DP, Long YC, Xiong LL, Xie B, Cai HQ. Observation on therapeutic effect of ultraviolet blood irradiation oxygen (UBIO) on chronic severe viral hepatitis [in Chinese]. Modern Diagnosis and Treatment 1999;10(2):85‐7.
Eiseman 1965 {published data only}
    1. Eiseman B, Liem DS, Raffucci F. Heterologous liver perfusion in treatment of hepatic failure. Annals of Surgery 1965;162(3):329‐45. - PMC - PubMed
Fu 1999 {published data only}
    1. Fu XY, Wang GS, Huang YC, Zhu JH, Hong LL. Artificial liver support combined with Chinese medicine in treating hepatic failure [in Chinese]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 1999;9(5):3‐4.
Fujita 1982 {published data only}
    1. Fujita Y, Ohiwa T, Kubota Y, Shimizu H, Yoshida S, Hosoya R, et al. Clinical trial of plasmapheresis in hepatic failure. Transaction ‐ American Society for Artificial Internal Organs 1982;28:225‐8. - PubMed
Hughes 1998 {published data only}
    1. Hughes RD, Nicolaou N, Langley PG, Ellis AJ, Wendon JA, Williams R. Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. Artificial Organs 1998;22(10):854‐8. - PubMed
Iizuka 1995 {published data only}
    1. Iizuka K, Kanesaka S, Akizawa T, Niikura K, Taira T, Kadokawa M, et al. Artificial liver support for the treatment of fulminant viral hepatic failure. Japanese Journal of Apheresis 1995;14(1):43‐5.
Jones 1998 {published data only}
    1. Jones CH, Goutcher E, Newstead CG, Will EJ, Dean SG, Davison AM. Hemodynamics and survival of patients with acute renal failure treated by continuous dialysis with two synthetic membranes. Artificial Organs 1998;22(8):638‐43. - PubMed
Koudahl 1971 {published data only}
    1. Koudahl G, Juul‐Nielsen J, Schmidt N, Winkler K, Tygstrup N. The function of the isolated pig liver cross‐perfused with anhepatic pigs and patients with liver failure. Scandinavian Journal of Gastroenterology 1971;9(Suppl):155‐60. [MEDLINE: ] - PubMed
Kukita 1990 {published data only}
    1. Kukita K, Kawamura A, Ariyama T, Meguro J, Yonekawa M, Imai K, et al. Rationality of plasma exchange therapy based on periodic liver CT volume calculation in patients with fulminant hepatitis. Progress in Clinical and Biological Research (Apheresis) 1990;337:237‐8. - PubMed
Larsen 1994 {published data only}
    1. Larsen FS, Hansen BA, Jorgensen LG, Secher NH, Bondesen S, Linkis P, et al. Cerebral blood flow velocity during high volume plasmapheresis in fulminant hepatic failure. The International Journal of Artificial Organs 1994;17(6):353‐61. - PubMed
Lepore 1970 {published data only}
    1. Lepore MJ, Martel AJ. Plasmapheresis with plasma exchange in hepatic coma. Annals of Internal Medicine 1970;72(2):165‐74. - PubMed
Li 1999 {published data only}
    1. Li LJ, Huang JR, Chen YM, Yang Q, Chen YG, Ma WH, et al. Use of artificial liver support system in the treatment of viral hepatitis gravis [in Chinese]. Chinese Journal of Infectious Diseases 1999;17(4):228‐30.
Matsumura 1987 {published data only}
    1. Matsumura KN, Guevara GR, Huston H, Hamilton WL, Riklmaru M, Yamasaki G, et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987;101:99‐103. - PubMed
Millis 1999a {published data only}
    1. Millis JM, Maguire P, Cronin DC, Conjeevarum H, Johnson R, Conlin C, et al. ELAD continuous liver support system: report of cell function. Hepatology 1999;30(4):168A.
Millis 1999b {published data only}
    1. Millis JM, Maguire P, Cronin DC, Conjeevarum H, Johnson R, Conlin C, et al. Continuous human liver support as a bridge to transplantation. Hepatology 1999;30(4):168A.
Mitzner 1996 {published data only}
    1. Mitzner SR, Stange J. Treatment of acute and chronic hepatic failure with the MARS system‐ clinical results. ASAIO Journal 1996;42(1):12.
Morgan 1997 {published data only}
    1. Morgan GR, Chen D, Goldenberg A, Tobias H, Diflo T, Teperman L. Plasma exchange (PEx) as a bridge to successful liver transplantation (OLT) in the critically ill patient. Hepatology 1997;26(4 Pt. 2):565A.
Morsiani 2002 {published data only}
    1. Morsiani E, Pazzi P, Puviani AC, Brogli M, Valieri L, Gorini P, et al. Early experiences with a porcine hepatocyte‐based bioartificial liver in acute hepatic failure patients. The International Journal of Artificial Organs 2002;25(3):192‐202. [MEDLINE: ] - PubMed
Munoz 1989 {published data only}
    1. Munoz SJ, Ballas SK, Moritz MJ, Martinez J, Friedman LS, Jarrell BE, et al. Perioperative management of fulminant and subfulminant hepatic failure with therapeutic plasmapheresis. Transplantation Proceedings 1989;21(3):3535‐6. - PubMed
Parbhoo 1971 {published data only}
    1. Parbhoo SP, Kennedy J, James IM, Chalstrey LJ, Ajdukiewicz A, Brock PJ, et al. Extracorporeal pig‐liver perfusion in treatment of hepatic coma due to fulminant hepatitis. The Lancet 1971;1(7701):659‐65. - PubMed
Ranek 1971 {published data only}
    1. Ranek L, Hansen RI, Hilden M, Ramsoe K, Schmidt A, Winkler K, et al. Pig liver perfusion in the treatment of acute hepatic failure. Scandinavian Journal of Gastroenterology 1971;9(Suppl):161‐9. [MEDLINE: ] - PubMed
Schmidt 2000 {published data only}
    1. Schmidt LE, Sorensen VR, Svendsen LB, Larsen FS, Stange J, Hansen BA. Improvement of systemic vascular resistance and arterial pressure in patients with acute on chronic liver failure during treatment with the molecular adsorbent recycling system (MARS). Hepatology 2000;32(4 Pt. 2):401A.
Sicot 1971 {published data only}
    1. Sicot C, Frejaville JP, Roche J, Rueff B, Benhamou JP, Fauvert R. 6 cases of severe hepatitis treated by interhuman crossed circulation. Annales de Medecine Interne (Paris) 1971;122(3):381‐7. [MEDLINE: ] - PubMed
Stange 1999 {published data only}
    1. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane‐based blood purification system for bioartificial liver support. Artificial Organs 1999;23(4):319‐30. - PubMed
Stange 2000 {published data only}
    1. Stange J, Mitzner SR, Klammt S, Freytag J, Peszynski P, Loock J, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transplantation 2000;6(5):603‐13. [MEDLINE: ] - PubMed
Sussman 1994 {published data only}
    1. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artificial Organs 1994;18:390‐6. - PubMed
Watanabe 1997a {published data only}
    1. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure: a phase I clinical trial. Annals of Surgery 1997;225(5):484‐94. [MEDLINE: ] - PMC - PubMed
Watanabe 1997b {published data only}
    1. Watanabe FD, Shackleton CR, Cohen SM, Goldman DE, Arnaout WS, Hewitt W, et al. Treatment of acetaminophen‐induced fulminant hepatic failure with a bioartificial liver. Transplantation Proceedings 1997;29:487‐8. - PubMed
Yoshiba 1996 {published data only}
    1. Yoshiba M, Inoue K, Sekiyama K, Koh I. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. Artificial Organs 1996;20(11):1169‐72. - PubMed
Zhou 2002 {published data only}
    1. Zhou X, Wang X, Yang Y, Zhao L, Miao J, Ding J, Fan D. Clinical research of patients with acute or chronic hepatic failure treated with molecular adsorbent recirculating system [in Chinese]. Chinese Journal of Hepatology 2002;10(3):213‐5. [MEDLINE: ] - PubMed

References to ongoing studies

Hayes 2000 {published data only}
    1. Hayes PC, et al. Developement of bioartificial liver assist device for use in patients with fulminant hepatic failure. The National Research Register 2000, issue 4.
Jalan 2002 {published data only}
    1. Jalan R, Steiner C, Kapoor d, Alisi A, Williams R. Molecular adsorbents recirculating system: early clinical experience in acute decompensation of chronic liver disease. Personal communication 2000.
VitaGen 2000 {unpublished data only}
    1. VitaGen Incorporated. FDA approved Phase I/II clinical trial to evaluate the safety of the ELAD artificial liver device in patients with FHF at six sites. VitaGen Incorporated 2000.

Additional references

Allen 2001
    1. Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology 2001;34(3):447‐55. - PubMed
Ash 1994
    1. Ash SR. Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. The International Journal of Artificial Organs 1994;18(5):355‐62. - PubMed
Ash 2000
    1. Ash SR, Steczko J, Knab WR, Blake DE, Carr DJ, Herker KD, Levy H. Push‐pull sorbent‐based pheresis and hemodiabsorption in the treatment of hepatic failure: preliminary results of a clinical trial with the BioLogic‐DTPF System. Therapeutic Apheresis 2000;4(3):218‐28. - PubMed
Benson 2000
    1. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. The New England Journal of Medicine 2000;342:1878‐86. - PubMed
Bonn 1996
    1. Bonn D. Hybrid devices offer hope for the failing liver. The Lancet 1996;348(9038):1372. - PubMed
Davenport 1991
    1. Davenport A, Will EJ, Davison AM. Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema. Contributions to Nephrology 1991;93:225‐33. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple graphical test. BMJ 1997;315:629‐34. [MEDLINE: ] - PMC - PubMed
Eguchi 2000
    1. Eguchi S, Kawazoe Y, Sugiyama N, Kawashita Y, Fujioka H, Furui J, et al. Effects of recombinant human hepatocyte growth factor on the proliferation and function of porcine hepatocytes. ASAIO Journal 2000;46(1):56‐9. - PubMed
Ellis 1996a
    1. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, Gislason GT, Sussman NL, et al. Pilot‐controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24(6):1446‐51. - PubMed
He 2000a
    1. He JQ, Chen CY, Deng JT, Qi HX, Zang XQ, Chen JQ. Charcoal hemoperfusion in the treatment of fulminant hepatic failure. Chinese Critical Care Medicine 2000;12(2):105‐8.
Hollis 1999
    1. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670‐4. [MEDLINE: ] - PMC - PubMed
Hughes 1994a
    1. Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R. Evaluation of the BioLogic‐DT sorbent‐suspension dialyser in patients with fulminant hepatic failure. The International Journal of Artificial Organs 1994;17(12):657‐62. - PubMed
Hughes 1996
    1. Hughes RD, Williams R. Use of bioartificial and artificial liver support devices. Seminars in Liver Disease 1996;16(4):435‐44. - PubMed
Hughes 1998b
    1. Hughes RD, Nicolaou N, Langley PG, Ellis AJ, Wendon JA, Williams R. Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. Artificial Organs 1998;22(10):854‐8. - PubMed
ICH‐GCP 1997
    1. International Conference on Harmonisation Expert Working Group. Code of Federal Regulations & International Conference on Harmonisation Guidelines. Pennsylvania: Parexel/Barnett, 1997; Vol. 1.
Juni 2001
    1. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6. [MEDLINE: ] - PMC - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed
Kunz 1998
    1. Kunz R, Oxman A. The unpredictability paradox: review of empirical comparisons of randomised and non‐randomised clinical trials. BMJ 1998;317:1185‐90. - PMC - PubMed
Kunz 2003
    1. Kunz R, Vist GE, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.MR000012.pub2] - DOI - PubMed
Lee 1993
    1. Lee WM. Acute liver failure. The New England Journal of Medicine 16‐12‐1993;329(25):1862‐72. - PubMed
Mitzner 2000a
    1. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transplantation 2000;6(3):277‐86. - PubMed
Mitzner 2001
    1. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R. Albumin dialysis using the molecular adsorbent recirculating system. Current Opinion in Nephrology and Hypertension 2001;10(6):777‐83. - PubMed
Mitzner 2001b
    1. Mitzner SR, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J, et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Therapeutic Apheresis 2001;5(5):417‐22. - PubMed
Mitzner 2001c
    1. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge‐Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. Journal of American Society of Nephrology 2001;12 Suppl 17:S75‐S82. - PubMed
Miwa 1996
    1. Miwa Y, Ellis AJ, Hughes RD, Langley PG, Wendon JA, Williams R. Effect of ELAD liver support on plasma HGF and TGF‐beta 1 in acute liver failure. The International Journal of Artificial Organs 1996;19(4):240‐4. - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses. The Lancet 1998;352:609‐13. - PubMed
Neuberger 1998
    1. Neuberger J, Adams D, MacMaster P, Maidment A, Speed M. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ 1998;317(7152):172‐5. - PMC - PubMed
O'Brien 1979
    1. O'Brien PC, Flemming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549‐56. - PubMed
Peto 1976
    1. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomised controlled trials requiring prolonged observation of each patient. 1. Introduction and design. British Journal of Cancer 1976;34:585‐612. - PMC - PubMed
Pocock 1993
    1. Pocock SJ. Statistical and ethical issues in monitoring clinical trials. Statistics in Medicine 1993;12:1459‐69. - PubMed
Pocock 2000
    1. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations?. The New England Journal of Medicine 2000;342:1907‐9. - PubMed
Rahman 1999
    1. Rahman TM, Hodgson HJ. Review article: liver support systems in acute hepatic failure. Alimentary Pharmacology and Therapeutics 1999;13(10):1255‐72. - PubMed
Riordan 1999
    1. Riordan SM, Williams R. Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis. Journal of Gastroenterology and Hepatology 1999;14:757‐70. - PubMed
Russell 1999
    1. Russell PS. Understanding resource use in liver transplantation. JAMA 1999;281(15):1431‐2. - PubMed
Sacks 1982
    1. Sacks H, Chalmers TC, Smith H. Randomized versus historical controls for clinical trials. American Journal of Medicine 1982;72(2):233‐40. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. JAMA 1995;273(5):408‐12. [MEDLINE: ] - PubMed
Sorkine 2001
    1. Sorkine P, Ben Abraham R, Szold O, Biderman P, Kidron A, Merchav H, et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Critical Care Medicine 2001;29(7):1332‐6. - PubMed
Stange 1995
    1. Stange J, Mitzner S, Strauss M, Fischer U, Lindemann S, Peters E, et al. Primary or established liver cells for a hybrid liver? Comparison of metabolic features. ASAIO Journal 1995;41(3):M310‐M315. - PubMed
Stange 1999a
    1. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane‐based blood purification system for bioartificial liver support. Artificial Organs 1999;23(4):319‐30. - PubMed
Stange 2000b
    1. Stange J, Mitzner SR, Klammt S, Freytag J, Peszynski P, Loock J, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transplantation 2000;6(5):603‐13. - PubMed
Stockmann 2000
    1. Stockmann HB, Hiemstra CA, Marquet RL, Ijzermans JN. Extracorporeal perfusion for the treatment of acute liver failure. Annals of Surgery 2000;231:460‐70. [MEDLINE: ] - PMC - PubMed
Sussman 1997
    1. Sussman NL, Kelly JH. Extracorporeal liver support: cell‐based therapy for the failing liver. American Journal of Kidney Disease 1997;30(5 Suppl 4):S66‐S71. - PubMed
Tandon 1999
    1. Tandon BN, Bernauau J, O'Grady J, Gupta SD, Krisch RE, Liaw YF, et al. Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. Journal of Gastroenterology and Hepatology 1999;14(5):403‐4. - PubMed
Wilkinson 1998b
    1. Wilkinson AH, Ash SR, Niessenson AR. Hemodiabsorption in treatment of hepatic failure. Journal of Tansplant Coordination 1998;8(1):43‐50. - PubMed

References to other published versions of this review

Kjaergard 2003
    1. Kjaergard LL, Liu J, Als‐Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute‐on‐chronic liver failure. A systematic review. JAMA 2003;289(2):217‐22. - PubMed

Publication types

MeSH terms

LinkOut - more resources